Clene submitted new data on CNM-Au8 to the FDA ahead of an upcoming meeting to discuss potential accelerated approval for the ALS therapy.| ALS News Today
The risk of death was nearly 60% lower in ALS patients given the experimental oral therapy CNM-Au8 than for an external placebo group, data show.| ALS News Today